Home › Metastatic Cancer › Arizona › Chandler
Metastatic Cancer clinical trials in Chandler, AZ
4 studies for Metastatic Cancer are looking for participants at sites in and around Chandler (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Ironwood Cancer & Research Centers, Chandler
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Ironwood Cancer & Research Centers, Chandler
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Ironwood Cancer & Research Centers, Chandler
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RecruitingPhase 2/3
- Ironwood Cancer & Research Centers, Chandler
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Chandler
- Steatotic Liver Disease10 studies
- Breast Cancer5 studies
- Non-Small Cell Lung Cancer5 studies
- Colorectal Cancer5 studies
- Obesity5 studies
- Digestive Diseases5 studies
- Liver Diseases4 studies
- Overweight4 studies
- Type 2 Diabetes4 studies
- Alzheimer's Disease3 studies
- Cardiovascular Disease3 studies
- Colon Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.